已有炎症性肠病患者使用免疫检查点抑制剂:回顾性病例系列
本文为回顾性病例系列,关注已确诊炎症性肠病(IBD)患者使用免疫检查点抑制剂(ICI)的情况。文中介绍ICI通过激活免疫系统发挥抗肿瘤作用,但可导致脱靶炎症和自身免疫反应,包括ICI诱导的结肠炎,据报道发生率高达13.6%。
要点
- ICI通过促进细胞毒性T细胞存活和抗肿瘤效应激活免疫系统。
- ICI可导致脱靶炎症和自身免疫,包括ICI诱导的结肠炎。
- ICI诱导的结肠炎据报道在高达13.6%的患者中发生。
核心结论
- 本文为已有IBD患者使用ICI的回顾性病例系列,原文未报告该系列的具体结论。
研究设计与样本
- 回顾性病例系列,研究对象为已确诊炎症性肠病(IBD)的患者。
主要发现
- ICI诱导的结肠炎据报道在高达13.6%的患者中发生。
关键数值与推荐
- 美国食品药品监督管理局目前批准7种ICI,靶点包括细胞毒性T淋巴细胞相关蛋白4(ipilimumab)、抗程序性细胞死亡1(PD-1)(nivolumab、pembrolizumab和cemiplimab)或抗PD配体1(atezolizumab、durvalumab和avelumab)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The etiology of inflammatory bowel disease (IBD) has yet to be fully understood; however, it is thought to be a result of genetic, immunologic, and environmental factors, including changes in the gut microbiome.1,2 Immune checkpoint inhibitors (ICI) have revolutionized treatment of advanced cancer. They activate the immune system by promoting cytotoxic T-cell survival and antitumor effects. A total of 7 ICIs currently are approved by the United States Food and Drug Administration, and target cytotoxic T lymphocyte-associated protein 4 (ipilimumab); anti-programmed cell death 1 (PD-1) (nivolumab, pembrolizumab, and cemiplimab), or anti-PD-ligand 1 (atezolizumab, durvalumab, and avelumab). However, by activating the immune system, these medications also can lead to off-target inflammation and autoimmunity, including ICI-induced colitis, which has been reported in up to 13.6% of patients.3.
引用
- Braga Neto MB, Ramos GP, Loftus EV, et al. Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series. Clin Gastroenterol Hepatol. 2020. PMID: 32565289. doi:10.1016/j.cgh.2020.06.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。